Company news

Genprex, Inc. news in 2022

Genprex, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh

December 14, 2022

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

December 13, 2022

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

August 15, 2022

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

August 14, 2022

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

May 4, 2022

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

March 30, 2022

Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

March 1, 2022

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

January 9, 2022

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

January 3, 2022

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

January 2, 2022

Decks in 2022